Company Overview
Snapshot
Founded in October 2019, Avertto Medical operates with 1–10 employees and has raised $3.7M across two funding rounds. The company was a finalist at the prestigious Marrakesh Forbes Aviram Competition and secured first place at the HUJI Asper Prize in 2023.
Business overview
Avertto Medical develops an AI-powered neck device designed for the early detection and monitoring of impending strokes. The company's solution utilizes neck sensors to continuously monitor for changes and alert responsive care teams, aiming to enable treatment within the critical 'golden hour' before neuronal injury occurs. Avertto targets the healthcare market, initially focusing on in-patient use with an external hospital monitor, with plans for a home-device insertable solution. Its business model leverages ICU disposable reimbursements in the US, strategically pricing its device to facilitate market penetration. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare, Patient Remote Monitoring, Medical Devices, and Medical Monitors, utilizing Artificial Intelligence, Platforms & Interfaces, Software, and Sensing technologies.
Strategic signal
In June 2023, Avertto Medical secured the Asper Prize from Hebrew University’s ASPER-HUJI Innovate, winning NIS 100,000 for its stroke-preventing technology. This recognition, following competition with 44 other startups, highlights the significant validation of Avertto's real-time stroke detection and prevention system, signaling strong potential for its innovative approach to improving patient outcomes and aligning with UN Sustainable Development Goals.
Log in to access full profile ›Company Intelligence Q&A
- What is Avertto Medical's core technology?
- Avertto Medical's core technology involves a neck device equipped with sensitive passive pressure sensors and a small wireless controller for continuous carotid recording. This system utilizes a highly accurate first threshold algorithm to detect large vessel occlusion, aiming to alert impending strokes before neuronal injury.
- What significant recognition did Avertto Medical receive in June 2023?
- In June 2023, Avertto Medical claimed the Asper Prize from Hebrew University’s ASPER-HUJI Innovate, winning NIS 100,000 for its stroke-preventing technology. This award recognized the company's system for real-time stroke detection and prevention through blood flow monitoring.
- What was Avertto Medical's achievement in May 2023?
- In May 2023, Avertto Medical was named one of the five finalists at The Aviram Awards 2023, a prestigious competition recognizing innovative startups.
- What is Avertto Medical's business model for market entry?
- Avertto Medical's business model is designed to generate revenue without relying on new reimbursement rates. In the US, the company leverages ICU disposable reimbursements, setting a sale price of $847 per patient for up to one week of use, which supports quick market infiltration.
- What clinical studies has Avertto Medical completed?
- Avertto Medical has completed Proof of Concept (POC) studies with 70 participants at Rabin, Galilee Medical Center in Israel, and VDH in Barcelona. Additionally, the company successfully conducted a space mission astronaut study with 4 participants during Axiom1.